Floatz logo

Vidutolimod

Stage IV Prostate Cancer AJCC v8

Emory Universitynucleic_acidPhase 2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Stage IV Prostate Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Bet Bromodomain Inhibitor Zen-3694
Rahul Aggarwal
Phase 2B
Rucaparib
Alliance for Clinical Trials in Oncology
Phase 3B
Golimumab
University of Washington
Phase 2CCC
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493
M.D. Anderson Cancer Center
Phase 2CCC
vx-970
National Cancer Institute (NCI)
Phase 2CCC

View all 31 →

Same molecule, other indications

Vidutolimod is also rated in:

melanomaDormant
CCC
Indicative ·
52 / 100
View asset →
metastatic melanomaDormant
CCC
Indicative ·
49 / 100
View asset →
lymph node cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →